AIP
NVO

ARS Investment Partners’s Novo Nordisk NVO Stock Holding History

ARS Investment Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Buy
288,970
+139,914
+94% +$6.01M 0.61% 40
2026
Q1 		$5.48M Sell
149,056
-19,504
-12% -$924K 0.28% 53
2025
Q4 		$8.58M Buy
168,560
+14,644
+10% +$749K 0.5% 45
2025
Q3 		$8.54M Buy
153,916
+63,155
+70% +$3.7M 0.56% 41
2025
Q2 		$6.26M Buy
+90,761
New +$6.17M 0.46% 42

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

ARS Investment Partners's NVO Position: Q2 2026 in Review

ARS Investment Partners increased its Novo Nordisk (NVO) stake by 94% in Q2 2026, buying an estimated $6.01M and bringing the position to 288,970 shares worth $13.9M. The position accounts for 0.61% of the portfolio, ranked #40.

ARS Investment Partners first reported a position in NVO in Q2 2025 and has held it in 5 quarters since. 385 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • ARS Investment Partners held 288,970 shares of Novo Nordisk worth $13.9M as of Q2 2026.
  • ARS Investment Partners bought 139,914 Novo Nordisk shares in Q2 2026, an estimated $6.01M.
  • Novo Nordisk made up 0.61% of ARS Investment Partners's portfolio in Q2 2026, its #40 holding.
  • ARS Investment Partners first reported a position in Novo Nordisk in Q2 2025 and has held it in 5 quarters since.
  • 385 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on ARS Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.